Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of “Buy” from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCTGet Free Report) has been assigned an average rating of “Buy” from the seven research firms that are covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $64.86.

Several analysts have commented on the stock. William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Thursday, May 23rd. Canaccord Genuity Group dropped their price objective on Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating for the company in a report on Friday, May 10th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a report on Wednesday, March 20th.

Get Our Latest Report on Arcturus Therapeutics

Insider Transactions at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 17,435 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $35.02, for a total value of $610,573.70. Following the completion of the transaction, the chief operating officer now directly owns 473,448 shares in the company, valued at approximately $16,580,148.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 52,114 shares of company stock valued at $1,955,824 over the last 90 days. 13.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Arcturus Therapeutics

Several institutional investors have recently added to or reduced their stakes in ARCT. Russell Investments Group Ltd. acquired a new stake in shares of Arcturus Therapeutics in the 1st quarter valued at about $40,000. AJOVista LLC acquired a new position in Arcturus Therapeutics during the fourth quarter worth $65,000. Quest Partners LLC bought a new position in Arcturus Therapeutics in the fourth quarter valued at $67,000. Public Employees Retirement System of Ohio acquired a new stake in Arcturus Therapeutics in the 4th quarter valued at $89,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Arcturus Therapeutics by 352.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock worth $97,000 after buying an additional 2,406 shares in the last quarter. 94.54% of the stock is owned by institutional investors.

Arcturus Therapeutics Stock Performance

Shares of ARCT opened at $31.00 on Friday. The firm has a market capitalization of $834.83 million, a price-to-earnings ratio of -7.93 and a beta of 2.76. Arcturus Therapeutics has a 52 week low of $17.52 and a 52 week high of $45.00. The business’s fifty day moving average price is $30.90 and its two-hundred day moving average price is $32.40.

Arcturus Therapeutics (NASDAQ:ARCTGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.00) EPS for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.17. The firm had revenue of $38.01 million during the quarter, compared to analyst estimates of $22.12 million. Arcturus Therapeutics had a negative return on equity of 37.61% and a negative net margin of 81.59%. As a group, research analysts forecast that Arcturus Therapeutics will post -4.39 EPS for the current year.

About Arcturus Therapeutics

(Get Free Report

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

Featured Articles

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with's FREE daily email newsletter.